Please login to the form below

Not currently logged in
Email:
Password:

Sir Tom Blundell to remain as chair of UK’s biotech research council

Reappointed to government role to support research

BBSRC Sir Tom BlundellSir Tom Blundell has been reappointed as chair of the UK's Biotechnology and Biological Sciences Research Council (BBSRC), a government-funded organisation to support research in the UK.

This is Sir Tom's second term in the position, having originally been appointed to the role in July 2009. He will now serve a further two years more than his original four-year term, with his reappointment lasting until June 30, 2015.

He was also one of the initial founders of the BBSRC in 1994, serving for two years as its chief executive.

“I am delighted that Sir Tom Blundell has agreed to remain as chair of BBSRC,” said David Willetts, minister for universities and science.

“His extensive academic experience in the field of biochemistry coupled with his active role in science policy makes him an invaluable asset to the council.”

This experience includes Sir Tom's current role as professor emeritus and director of research in biochemistry at the University of Cambridge. 

He was previously head of the School of Biological Sciences in Cambridge and Sir William Dunn Professor of Biochemistry.

Sir Tom has prior experience in science policy, serving as a member of the advisory group to the Prime Minister in the 1980s.

He has also spent time as chairman of the Royal Commission on Environmental Pollution, president of the UK Biosciences Federation and president of UK Science Council.

In addition to his academic and policy background, Sir Tom has industry experience, serving as non-executive director of biotech Celltech from 1996 to 2005 and holding advisory roles with Pfizer, UCB and SmithKline Beecham (now part of GSK).

27th February 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics